News
The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback